🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 18 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 31/08/2001 | 37,10 | 37,39 | 36,39 | 36,89 | -1,50% | 2,70% | 568.200 |
| 30/08/2001 | 38,38 | 39,34 | 36,85 | 37,45 | -3,48% | 6,49% | 758.000 |
| 29/08/2001 | 38,05 | 39,22 | 37,20 | 38,80 | +1,94% | 5,31% | 473.400 |
| 28/08/2001 | 38,90 | 39,19 | 37,72 | 38,06 | -2,21% | 3,78% | 838.600 |
| 27/08/2001 | 39,10 | 39,67 | 38,40 | 38,92 | -0,46% | 3,25% | 494.900 |
| 24/08/2001 | 38,34 | 39,42 | 38,00 | 39,10 | +2,06% | 3,70% | 818.900 |
| 23/08/2001 | 36,06 | 38,70 | 35,97 | 38,31 | +6,21% | 7,57% | 622.100 |
| 22/08/2001 | 35,00 | 36,42 | 34,26 | 36,07 | +3,53% | 6,17% | 597.000 |
| 21/08/2001 | 35,50 | 37,04 | 34,33 | 34,84 | -3,22% | 7,63% | 468.300 |
| 20/08/2001 | 35,55 | 36,36 | 35,50 | 36,00 | +0,00% | 2,42% | 381.800 |
| 17/08/2001 | 36,18 | 36,50 | 35,75 | 36,00 | -3,61% | 2,07% | 483.600 |
| 16/08/2001 | 37,80 | 38,00 | 36,52 | 37,35 | -1,99% | 3,92% | 486.300 |
| 15/08/2001 | 38,34 | 39,13 | 37,55 | 38,11 | -0,60% | 4,12% | 892.400 |
| 14/08/2001 | 38,65 | 39,38 | 37,15 | 38,34 | +1,72% | 5,77% | 896.200 |
| 13/08/2001 | 35,80 | 37,93 | 35,79 | 37,69 | +5,75% | 5,98% | 1.030.700 |
| 10/08/2001 | 35,28 | 36,30 | 34,59 | 35,64 | +2,15% | 4,85% | 535.000 |
| 09/08/2001 | 35,43 | 35,44 | 33,30 | 34,89 | -2,10% | 6,04% | 931.400 |
| 08/08/2001 | 36,15 | 37,60 | 35,53 | 35,64 | -2,06% | 5,73% | 932.700 |
| 07/08/2001 | 39,05 | 39,09 | 35,94 | 36,39 | -6,79% | 8,07% | 1.342.000 |
| 06/08/2001 | 39,45 | 40,38 | 39,04 | 39,04 | -2,23% | 3,40% | 388.300 |
| 03/08/2001 | 39,30 | 40,76 | 39,08 | 39,93 | +0,58% | 4,27% | 416.000 |
| 02/08/2001 | 40,69 | 41,35 | 39,20 | 39,70 | -1,66% | 5,28% | 418.000 |
| 01/08/2001 | 40,01 | 41,30 | 39,97 | 40,37 | +1,05% | 3,32% | 386.600 |
| 31/07/2001 | 41,73 | 41,76 | 39,35 | 39,95 | -3,39% | 5,78% | 716.600 |
| 30/07/2001 | 42,95 | 43,37 | 40,50 | 41,35 | -3,41% | 6,68% | 589.700 |
| 27/07/2001 | 42,50 | 43,24 | 41,24 | 42,81 | +2,51% | 4,71% | 548.400 |
| 26/07/2001 | 41,55 | 42,50 | 41,21 | 41,76 | +0,51% | 3,10% | 1.019.200 |
| 25/07/2001 | 42,19 | 43,09 | 41,21 | 41,55 | +0,19% | 4,46% | 1.172.700 |
| 24/07/2001 | 44,02 | 44,07 | 41,45 | 41,47 | -5,62% | 5,95% | 1.155.200 |
| 23/07/2001 | 44,10 | 45,56 | 42,75 | 43,94 | -0,18% | 6,37% | 946.100 |